AC
ACXP.US Acurx Pharmaceuticals LLC
- Market cap
- USD 5.97M
- P/E
- -
- P/B
- 0.69x
- ROE
- -96.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ACXP.US undervalued?
Graham numberThe Graham number of Acurx Pharmaceuticals LLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Acurx Pharmaceuticals LLC fundamental analysis
No fundamental analysis for Acurx Pharmaceuticals LLC yet.
Acurx Pharmaceuticals LLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including met…
Full company profileAcurx Pharmaceuticals LLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Acurx Pharmaceuticals LLC annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.93M | -4.60M | -12.9M | -12.1M | -14.6M | -14.1M | -8.09M | -8.05M |
| EBITDA | -5.93M | -4.60M | -12.8M | -12.1M | -14.6M | 20.1K | -7.97M | -7.98M |
| Net Income | -5.93M | -4.60M | -12.7M | -12.1M | -14.6M | -14.1M | -7.97M | -7.87M |
| EPS | -12 | -9.28 | -25 | -22 | -23 | -17 | -5.31 | -1.85 |
| Balance Sheet | ||||||||
| Total Assets | 2.53M | 3.22M | 13.3M | 9.38M | 7.71M | 3.86M | 7.69M | 11.0M |
| Total Liabilities | 1.71M | 522K | 844K | 2.06M | 3.04M | 3.24M | 2.42M | 2.83M |
| Shareholders' Equity | 820K | 2.70M | 12.4M | 7.32M | 4.67M | 615K | 5.27M | 8.15M |
| Cash & Short-term Investments | 2.48M | 3.18M | 13.0M | 9.11M | 7.47M | 3.71M | 7.56M | 10.7M |
| Total Debt | - | 66.5K | - | - | - | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.99M | -3.35M | -5.01M | -7.54M | -9.80M | -10.4M | -6.79M | -6.23M |
| Capital Expenditure | 0.00 | 0.00 | 3.00 | 0.00 | 5.00 | 0.00 | 0.00 | 6.00 |
| Free Cash Flow | -3.99M | -3.35M | -5.01M | -7.54M | -9.80M | -10.4M | -6.79M | -6.23M |
| Ratios | ||||||||
| ROE | -723.5% | -170.3% | -102.2% | -165.3% | -312.4% | -2,292.7% | -151.2% | -96.5% |
| ROA | -234.3% | -142.7% | -95.7% | -129.0% | -189.1% | -365.6% | -103.6% | -71.6% |
| Debt to Equity | - | 0.02x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Acurx Pharmaceuticals LLC dividends
Acurx Pharmaceuticals LLC has not paid dividends in the last 7 fiscal years.
Last stock split: 1:20 on Aug 5, 2025.
Who owns Acurx Pharmaceuticals LLC
- Insiders 2.31%
- Institutions 4.11%
- Public & others 93.58%
- Shares outstanding 6.06M
- Free float 5.14M
Top funds holding ACXP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 21.3K | 0.39% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.98K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 1.00K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding ACXP.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 31.1K | 0.56% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 26.4K | 0.48% | +6.41% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 16.2K | 0.29% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 15.7K | 0.28% | -71.22% | Jun 2026 |
| Prospect Financial Services Llc | 13.8K | 0.25% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 7.50K | 0.13% | +15.38% | Jun 2026 |
| Integrated Wealth Concepts LLC | 4.73K | 0.09% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 2.74K | 0.05% | +166.15% | Jun 2026 |
| Wells Fargo & Co | 2.30K | 0.04% | 0.00% | Jun 2026 |
| Westside Investment Management, Inc. | 1.65K | 0.03% | 0.00% | Jun 2026 |
| Nbc Securities Inc | 1.50K | 0.03% | 0.00% | Jun 2026 |
| Barclays PLC | 281.00 | 0.01% | -26.05% | Jun 2026 |
| Cornerstone Planning Group LLC | 167.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 100.00 | 0.00% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 95.00 | 0.00% | -61.22% | Jun 2026 |
| BlackRock Inc | 60.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 23.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 6.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 3.00 | 0.00% | -99.95% | Jun 2026 |
| MCGUIRE CAPITAL ADVISORS INC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Acurx Pharmaceuticals LLC company profile
- Company name
- Acurx Pharmaceuticals LLC
- Ticker
- ACXP.US
- Exchange
- USA Stocks
- Listed since
- Jun 25, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 259 Liberty Avenue, Staten Island, NY, United States, 10305
- Phone
- 917 533 1469
- Website
- acurxpharma.com
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals LLC management
4- Mr. Robert J. DeLucciaCo-Founder & Executive Chairman · born 1946
- Mr. David P. Luci CPA, Esq., J.D.Co-Founder, President, CEO, Corporate Secretary & Director · born 1967
- Mr. Robert G. Shawah CPACo-Founder & CFO · born 1967
- Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D.Medical Director · born 1948